DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Wednesday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright dropped their target price on DBV Technologies from $10.00 to $5.00 and set a buy rating for the company in a research report on Wednesday, May 8th.

DBV Technologies Trading Up 1.1 %

Shares of NASDAQ:DBVT opened at $0.62 on Wednesday. The business has a 50-day moving average price of $0.70 and a 200 day moving average price of $0.81. The company has a market capitalization of $119.17 million, a price-to-earnings ratio of -1.47 and a beta of 0.73. DBV Technologies has a 12-month low of $0.42 and a 12-month high of $2.26.

Shares of DBV Technologies are set to reverse split on the morning of Monday, June 3rd. The 1-2 reverse split was announced on Monday, June 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 3rd.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.10. The company had revenue of $8.88 million during the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. During the same period in the previous year, the company posted ($0.23) EPS. As a group, equities research analysts predict that DBV Technologies will post -0.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies by 6.2% in the 1st quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock valued at $4,172,000 after buying an additional 327,345 shares during the period. Cowen AND Company LLC purchased a new position in shares of DBV Technologies in the 4th quarter valued at about $49,000. Optiver Holding B.V. boosted its stake in shares of DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after buying an additional 235,337 shares during the period. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of DBV Technologies in the 3rd quarter valued at about $94,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.